HAE · Haemonetics Corp

Track HAE — free

$119.47 +17.76 (+17.46%) At close · Oct 8

S&P 400 member Russell 2000 member Rebalance outlook locked

Market Cap

$5.44B

45.50M

Volume · Oct 8 2.78M Avg daily vol (3M) 711.24K

Up next

Next earnings call

Nov 5, 2026 Scheduled · in 4 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q1 2027 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$1.35B

Trailing 12 months

Net income (TTM)

$96.29M

Trailing 12 months

Revenue growth YoY

+5.6%

Year over year

Operating margin

11.9%

Trailing 12 months

P / E (TTM)

49.1

Trailing earnings · reciprocal yield 2.0%

FCF yield

6.3%

TTM · current market cap

Return on invested capital

6.6%

Trailing 12 months

Net cash

−$950.77M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-5.5%

Year over year · fewer shares

Price change (1Y)

+106.5%

Trailing year

Short interest

7.5%

Latest settlement · 5.7 days to cover

View all 115 metrics

AI Brief

Q1 FY27 earnings call · Aug 6, 2026

Q1 FY27

TL;DR. Haemonetics reported Q1 FY27 revenue of $339 million, up 5.6% reported and 5.9% organic, with adjusted EPS of $1.14 (+3.6%) and raised full-year FY27 reported revenue growth guidance to 5-8% (from 4-7%) and organic growth to 4-7% (from 3-6%), driven by broad-based strength across Apheresis, Blood Management Technologies, and a return to growth in Interventional Technologies.

Bullish

+ Raised FY27 Apheresis revenue growth guidance to low- to mid-single digits on Q1 outperformance
+ Q1 organic revenue grew 5.9% with broad-based contribution across all three core platforms
+ Blood Management Technologies grew 8% organic with mid-teens disposable growth in hemostasis management
+ Plasma revenue grew 8% organic with North American disposables up mid-20% and EMEA up double-digits
+ Vascular closure returned to low double-digit growth driven by Vascade MVP XL label expansion and improved PFA stability
+ Free cash flow conversion reached 106% of adjusted net income on trailing 12-month basis

Bearish

− Adjusted gross margin declined 40 bps YoY to 60.4% and adjusted operating margin declined 70 bps to 23.4%
− Adjusted tax rate rose to 25.7% from 24.9% due to lower tax benefits on equity compensation

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.62

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +58%

above

Price vs 50-day avg +18%

above

RSI (14) 77

overbought

MACD trend Positive

52-week position 100%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +18%

trailing

6-month return +94%

trailing

YTD return +49%

this year

Relative strength +85%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $101 › 200d $76 — 50d above 200d

Institutional flow Distributing

7 of 332 funds reported for Sep 30 · net -6.5K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

7.53% of float · ▲ +19.6% MoM · 5.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

332 holders — near 3-yr high, broad support

Squeeze score 88

high risk · 0–100

Fundamentals

Fair

Revenue growth −3%

Y/Y

Gross margin 87%

expanding

EPS growth −38%

Y/Y

Free cash flow $260.4M

Buyback $325.0M

remaining

Balance sheet $979.1M

net debt

Quant / Vol

risk profile

Very High

Volatility 52%

annualized · 1-yr

Max drawdown −40%

past year

ATR 3.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 6, 2026

Reported Revenue · fiscal 2027 Initiated 5% – 8%

Organic Revenue · fiscal 2027 Non-GAAP Initiated 4% – 7%

Free cash flow conversion · fiscal 2027 Non-GAAP Initiated 80%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+58% Bullish

Price vs 50-day avg

+18% Bullish

RSI (14)

77 Bearish

MACD trend

Positive Bullish

52-week position

100% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $101 › 200d $76 — 50d above 200d

Institutional flow Distributing

7 of 332 funds reported for Sep 30 · net -6.5K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

7.53% of float · ▲ +19.6% MoM · 5.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

332 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $49 Now $119 · 100% Range high $119

vs 200-day avg +58% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted earnings per diluted share non-GAAP	$1.14	Q1 FY2027	—
GAAP → non-GAAP reconciliation GAAP Earnings per diluted share $0.72 +$0.16 Amortization of acquired intangible assets +$0.07 Integration and transaction costs +$0.04 Restructuring costs +$0 Restructuring related costs +$0.1 Digital transformation costs +$0.01 Litigation-related charges +$0.02 Equity method losses +$0.02 Discrete tax items = Adjusted earnings per diluted share $1.14
Adjusted gross margin non-GAAP	60.4%	Q1 FY2027	—
Adjusted gross profit non-GAAP	$204.88M	Three Months Ended June 27, 2026	—
GAAP → non-GAAP reconciliation GAAP Gross profit $202.8M +$0K Amortization of acquired intangible assets +$1.29M Integration and transaction costs +$783K Restructuring costs +$10K Restructuring related costs +$0K Digital transformation costs +$0K Litigation-related charges +$0K Equity method losses +$0K Discrete tax items = Adjusted gross profit $204.88M
Adjusted income tax rate non-GAAP	25.7%	Q1 FY2027	—
Adjusted net income non-GAAP	$52.3M	Q1 FY2027	—
GAAP → non-GAAP reconciliation GAAP Net income $33.01M +$7.92M Amortization of acquired intangible assets +$3.14M Integration and transaction costs +$1.76M Restructuring costs -$40K Restructuring related costs +$4.6M Digital transformation costs +$457K Litigation-related charges +$745K Equity method losses +$696K Discrete tax items = Adjusted net income $52.29M
Adjusted operating expenses non-GAAP	$125.6M	Q1 FY2027	—
GAAP → non-GAAP reconciliation GAAP Operating expenses $145.35M -$10.2M Amortization of acquired intangible assets -$1.43M Integration and transaction costs -$1.52M Restructuring costs +$50K Restructuring related costs -$6.16M Digital transformation costs -$457K Litigation-related charges +$0K Equity method losses +$0K Discrete tax items = Adjusted operating expenses $125.62M
Adjusted operating income non-GAAP	$79.3M	Q1 FY2027	—
GAAP → non-GAAP reconciliation GAAP Operating income $57.46M +$10.2M Amortization of acquired intangible assets +$2.72M Integration and transaction costs +$2.3M Restructuring costs -$40K Restructuring related costs +$6.16M Digital transformation costs +$457K Litigation-related charges +$0K Equity method losses +$0K Discrete tax items = Adjusted operating income $79.26M
Adjusted operating margin non-GAAP	23.4%	Q1 FY2027	—
Cash flow from operating activities	$52M	Q1 FY2027	—
Free cash flow non-GAAP	$39M	Q1 FY2027	—
GAAP → non-GAAP reconciliation GAAP Cash provided by operating activities $52.32M -$7.91M Capital expenditures -$5.57M Additions to Haemonetics equipment +$237K Proceeds from sale of property, plant and equipment = Free cash flow $39.09M
Organic revenue increase non-GAAP	5.9%	Q1 FY2027	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
HAE Haemonetics Corp this stock	$5.44B	+49.1%	-3.0%	—	7.5%
ABT Abbott Laboratories	$171.97B	-21.4%	+5.7%	27.7	1.1%
MDT Medtronic plc	$112.24B	-8.7%	+8.4%	21.6	1.3%
SYK Stryker Corp	$105.64B	-21.2%	+11.2%	28.5	2.0%
BSX Boston Scientific Corp	$60.69B	-55.9%	+12.5%	17.0	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

332

% held: 110.1%
Reported: 7 of 332
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

404

View

Short & Settlement

Short Interest Rising

Shares short

3.4M

Days to cover: 5.7d
Change: +561.2K sh

View

Short Volume

Short vol %

54%

As of: Oct 8, 2026

Short Total

View

Fails to Deliver

FTD shares

1.9K

Value: $205.0K
As of: Aug 21, 2026

View

Off-Exchange

Off-exchange %

45.8%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Lois Frankel

Amount: $1.0K–$15.0K
Traded: May 7, 2021

View

Financials

Revenue (FY)

$1.3B

Net income (FY): $97.3M
EPS diluted: $2.05

View

Buybacks

Remaining

$325.0M

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 8, 2026
This year: 15

View

Proposed Sales

Value

$1.4M

Shares: 18.6K
Filed: Jun 26, 2025

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 5, 2026

Last webcast: Aug 6, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
HAE	+14.5%	+18.2%	+93.9%	+13.5%	+49.1%
SPY	+1.3%	+2.1%	+9.0%	+1.5%	+13.5%
vs SPY	+13.2%	+16.1%	+84.9%	+12.0%	+35.6%

Capital returns

Buyback program · as of Jun 27, 2026

Authorized

—

Spent (derived)

—

Remaining

$325.00M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 313143 CUSIP 405024100 13F (30d) 11 filings 11 filers Visit website Investor relations

HAE · Haemonetics Corp

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns